FREE PREMIUM SUBSCRIPTION FOR 14 DAYS!

Blueprint Medicines Corporation Stock Forecast NASDAQ:BPMC

Price Target and Analyst Ratings

Most Recent Rating

On July 30, 2021 "Morgan Stanley" gave "$101.00 - $96.00" rating for BPMC. The price target was set to $85.90+1.4%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-07-30 $101.00 - $96.00 Target Lowered by Morgan Stanley $87.87 $85.90+1.4%
2021-06-17 Outperform Target Raised by SVB Leerink $83.53 $127.00 → $137.00
2021-06-17 Outperform Target Raised by Robert W. Baird $83.53 $119.00 → $123.00
2021-06-17 Outperform Target Lowered by Wedbush $83.53 $136.00 → $130.00
2021-05-06 Equal Weight Target Lowered by Morgan Stanley $93.18 $105.00 → $101.00
2021-04-30 Equal Weight Target Lowered by Morgan Stanley $96.32 $105.00 → $101.00
2021-04-19 Outperform Target Raised by Wedbush $93.81 $119.00 → $136.00
2021-04-13 Outperform Target Raised by Wedbush $93.08 $119.00 → $136.00
2021-04-13 Outperform Reiterated by Wedbush $93.08 $119.00 → $136.00
2021-03-30 Neutral Initiated by Credit Suisse Group $93.27
2021-02-25 Equal Weight Target Lowered by Morgan Stanley $96.09 $112.00 → $105.00
2021-02-25 Equal Weight Target Raised by Barclays $96.09 $90.00 → $95.00
2021-02-18 Buy Reiterated by HC Wainwright $96.74
2021-02-18 Equal Weight Target Raised by Barclays $96.74 $90.00 → $95.00
2021-01-12 Positive - Outperform Target Raised by SVB Leerink $107.22 $121.00 → $127.00
2021-01-12 Outperform Target Raised by SVB Leerink $107.22 $121.00 → $127.00
2020-12-18 Outperform Target Raised by JMP Securities $123.64 $118.00 → $152.00
2020-12-14 Outperform Target Raised by BMO Capital Markets $117.31 $113.00 → $132.00
2020-12-02 Hold Initiated by Stifel Nicolaus $105.61
2020-11-02 Buy - Hold Downgraded by Jefferies Financial Group $98.47 $90.00 → $96.00
2020-11-02 Buy Target Raised by HC Wainwright $98.47 $110.00 → $135.00
2020-10-30 Overweight - Equal Weight Downgraded by Morgan Stanley $102.28 $112.00
2020-10-30 Target Raised by Wedbush $102.28 $102.00 → $115.00
2020-10-29 Neutral Target Raised by Piper Sandler $106.84 $77.00 → $81.00
2020-10-16 Positive - Strong-Buy Target Raised by Raymond James $102.33 $106.00 → $122.00
2020-10-13 Overweight Target Raised by Morgan Stanley $100.22 $92.00 → $100.00
2020-09-23 Equal Weight Target Raised by Barclays $89.64 $77.00 → $90.00
2020-09-23 Outperform Target Raised by BMO Capital Markets $89.64 $105.00 → $113.00
2020-09-23 Outperform Target Raised by SVB Leerink $89.64 $107.00 → $121.00
2020-09-22 Buy Reiterated by Raymond James $87.27
2020-09-02 Buy Reiterated by Raymond James $77.06
2020-07-31 Buy Reiterated by HC Wainwright $73.18
2020-07-27 Outperform Target Raised by SVB Leerink $75.76 $106.00 → $107.00
2020-07-27 Outperform Target Raised by SVB Leerink $75.76 $106.00 → $107.00
2020-06-08 Positive - Buy Target Raised by Deutsche Bank $74.30 $70.00 → $85.00
2020-06-08 Outperform Target Raised by BMO Capital Markets $74.30 $75.00 → $111.00
2020-05-07 Buy Reiterated by HC Wainwright $60.18 $66.00
2020-04-30 Overweight Target Lowered by Morgan Stanley $58.83 $103.00 → $88.00
2020-04-30 Buy Target Lowered by Canaccord Genuity $58.83 $115.00 → $100.00
2020-04-29 Outperform Target Lowered by BMO Capital Markets $60.13 $89.00 → $75.00
2020-04-29 Outperform Target Lowered by SVB Leerink $60.13 $125.00 → $105.00
2020-04-29 Buy Target Lowered by HC Wainwright $60.13 $100.00 → $66.00
2020-04-29 Market Outperform Target Lowered by JMP Securities $60.13 $107.00 → $103.00

BPMC Stock Trend

The stockhas broken the wide and falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction, there will be support on the roof of the current trend broken, which is $86.21, a level that may pose a second chance to hit a runner. According to fan-theory $95.02 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

Data

Date Bottom Mid Top
2021-08-03 $77.21 $81.61 $86.02
2021-08-04 $77.02 $81.42 $85.83
2021-08-05 $76.82 $81.23 $85.63
2021-08-06 $76.63 $81.04 $85.44
2021-08-09 $76.44 $80.84 $85.25
2021-08-10 $76.25 $80.65 $85.06
2021-08-11 $76.06 $80.46 $84.86
2021-08-12 $75.86 $80.27 $84.67
2021-08-13 $75.67 $80.08 $84.48
2021-08-16 $75.48 $79.88 $84.29
2021-08-17 $75.29 $79.69 $84.10
2021-08-18 $75.10 $79.50 $83.90
2021-08-19 $74.90 $79.31 $83.71
2021-08-20 $74.71 $79.12 $83.52
2021-08-23 $74.52 $78.92 $83.33
2021-08-24 $74.33 $78.73 $83.14
2021-08-25 $74.14 $78.54 $82.94
2021-08-26 $73.94 $78.35 $82.75
2021-08-27 $73.75 $78.16 $82.56
2021-08-30 $73.56 $77.96 $82.37
2021-08-31 $73.37 $77.77 $82.18
2021-09-01 $73.17 $77.58 $81.98
2021-09-02 $72.98 $77.39 $81.79
2021-09-03 $72.79 $77.19 $81.60
2021-09-07 $72.60 $77.00 $81.41
2021-09-08 $72.41 $76.81 $81.21
2021-09-09 $72.21 $76.62 $81.02
2021-09-10 $72.02 $76.43 $80.83
2021-09-13 $71.83 $76.23 $80.64
2021-09-14 $71.64 $76.04 $80.45

About Blueprint Medicines Corporation

Blueprint Medicines Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patie... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT